Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal optical imaging for the assessment of the teratogenic effects of ethanol on zebrafish development.

Journal of biomedical optics·2026
Same author

Clinical multimodal Brillouin microscopy-optical coherence elastography system for lens biomechanics.

Journal of biomedical optics·2025
Same author

Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer.

Cancer immunology research·2025
Same author

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control.

Journal for immunotherapy of cancer·2025
Same author

Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen.

PloS one·2025
Same author

The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy.

Science advances·2024

Related Experiment Video

Updated: Jul 19, 2025

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.2K

Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition.

Satish Kumar R Noonepalle1, Scott Grindrod2, Nima Aghdam3

  • 1Department of Oncology, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia.

Molecular Cancer Therapeutics
|August 16, 2023
PubMed
Summary
This summary is machine-generated.

Targeting histone deacetylase 6 (HDAC6) with a novel inhibitor prevents M2 macrophage polarization after radiotherapy, enhancing antitumor immunity and reducing tumor relapse. This combination therapy shows promise for improved cancer treatment outcomes.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

428
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K

Related Experiment Videos

Last Updated: Jul 19, 2025

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

428
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Radiotherapy (RT) is a cornerstone cancer treatment that triggers antitumor immunity.
  • RT can induce a shift from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages, promoting tumor resistance and relapse.
  • Histone deacetylase 6 (HDAC6) is implicated in regulating macrophage polarization and immune responses.

Purpose of the Study:

  • To investigate the potential of targeting HDAC6 with a selective inhibitor (SP-2-225) to enhance radiotherapy's antitumor effects.
  • To evaluate the impact of HDAC6 inhibition on macrophage polarization within the tumor microenvironment after radiotherapy.

Main Methods:

  • Utilized a novel selective HDAC6 inhibitor, SP-2-225, in combination with radiotherapy.
  • Assessed tumor growth and macrophage polarization (M1/M2 ratio) in the tumor microenvironment.

Main Results:

  • Combination therapy with SP-2-225 and radiotherapy significantly decreased tumor growth.
  • Treatment enhanced the M1/M2 macrophage ratio within tumors, indicating a shift towards an antitumor immune response.

Conclusions:

  • Selective inhibition of HDAC6 can reprogram macrophages to an M1 phenotype, augmenting the antitumor immune response induced by radiotherapy.
  • Targeting HDAC6 presents a viable strategy for combination therapy to improve radiotherapy efficacy and prevent tumor relapse.